English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Prior to pre-exposure treatment of cats with two mouse-cat chimeric antibodies, FJH2 and F1D7, having neutralizing activity to feline herpesvirus-1 (FHV-1) and cat calicivirus (FCV), respectively, these chimeric antibodies were labeled with (125)I and administered to cats to examine their blood kinetics. Concentrations of the both administered chimeric antibodies in the blood reached maximum at the 48th hour post-administration, and the level was 34% for FJH2 and 54% for F1D7. Then the concentration levels declined gently, and decreased afterwards to 8.2% for FJH2 and 25% for F1D7 on the 20th day post-administration. The blood half-lives of FJH2 and F1D7 were 8.3 days and 10.7 days, respectively. In order to examine effectiveness in pre-exposure treatment of cats with these chimeric antibodies, cats were administered on the 15th day prior to the challenge infections with FHV-1 and FCV by subcutaneous route with 0.5 ml/kg of an FJH-F1D7 mixture being adjusted to contain each chimeric antibody of 10 mg/ml. The cats that received the pre-exposure treatment with the cocktail, showed obvious reductions in manifestations of symptoms caused by those viral infections. The protective effectiveness of the pre-exposure treatment against these viral challenge infections was almost equal to that of the treatment given at right after these challenge infections.

Pre-exposure Treatment of Cats with Anti-FHV-1 and Anti-FCV Mouse-Cat Chimeric Antibodies